In order to improve the curative effect of Lenvatinib and develop new medications to improve the prognosis in patients with HCC, additional research should be done to explore the precise mechanism of TM4SF1 affecting lenvatinib resistance in HCC. Here, TM4SF1 is linked to hepatocellular carcinoma.